Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.50 |
| ▸ | CCR3 | P51677 | 2/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14412209 | 0.90 | HTR7 (0.52) | SLC6A2SLC6A4OPRM1MAOBMEN1 | |
| SCHEMBL5454553 | 0.86 | HTR2A (0.47) | HTR2AMEN1KMT2A | |
| SCHEMBL5446464 | 0.84 | MAPT (0.50) | HTR2AMAPTMEN1KMT2A | |
| SCHEMBL5454585 | 0.84 | CNR2 (0.47) | HTR2A | |
| SCHEMBL5441664 | 0.81 | CNR2 (0.45) | HTR2AMAPT | |
| SCHEMBL14412213 | 0.81 | HTR1A (0.51) | SLC6A4HTR2AMAPTMAOBMEN1 | |
| SCHEMBL5451215 | 0.81 | ADRA1D (0.45) | HTR2A | |
| Hydrochloric Acid SCHEMBL5448668 | 0.80 | ADRA1D (0.47) | MAPT | |
| SCHEMBL5454485 | 0.78 | ALOX15 (0.47) | HTR2AMAPTMEN1KMT2A | |
| SCHEMBL14411765 | 0.77 | CNR2 (0.48) | HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | GIPR, GHSR, GHRHR | SLC6A2 1034/4885SLC6A4 1446/4885OPRM1 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.